Shots:
- Health Canada has approved Keytruda + pemetrexed + Pt-based CT as 1L treatment of unresectable advanced or metastatic MPM based on P-II/III (IND.227/KEYNOTE-483) trial led by CCTG in collaboration with NCIN & IFCT
- Trial assessed the regimen in MPM pts (n=440) who received either Keytruda (200mg, IV) + pemetrexed (500mg/m^2) & Pt-based CT on Day 1 of each 21-day cycle for 6 cycles followed by Keytruda for Q3W or pemetrexed + Pt-based CT for 6 cycles
- Study showed improved OS (mOS: 17.3 vs 16.1mos.), a 21% reduction in death risk & improved PFS (mPFS: 7.1mos. in both arms), with ORR of 52% vs 29%
Ref: Merck | Image: Merck
Related News:- Merck Signs a ~$493M Deal with Cyprumed to Develop Oral Peptide Therapeutics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
